the aid library

LIST OPTIONS

Filter

8059

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (241)

View PDF (285)

Приоритетные аспекты изучения проблемы ТБ/ВИЧ в условиях высокой распространенности ВИЧ-инфекции и ограниченных ресурсов

Delphine Sculier, Haileyesus Getahun, Reuben Granich World Health Organization, TB HIV working group, Stop TB Partnership (2011) C_WHO

Цель этого документа – повысить уровень осознания актуальности приоритетных направлений научных исследований по проблеме ТБ/ВИЧ (то есть по тем направлениям, кот... more

Download (232)

View PDF (238)

Quick Reference Guide - Diabetes

Diabetes Canada (2018) CC

Download (332)

View PDF (247)

WHO manual for HIV drug resistance testing using dried blood spot specimens

World Health Organization WHO (2020) C_WHO

HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it ... more

Download (184)

View PDF (229)

Vaccination as a precaution for healthy aging. 12 questions and answers

Bundesarbeitsgemeinschaft der Seniorenorganisationen e.V. (BAGSO) (2021) C2

Der BAGSO-Ratgeber informiert kompakt und verständlich zu Impfungen für Erwachsene ab 60 Jahren. Er gibt Antworten auf zwölf häufig gestellte Fragen, u.a. für wen welche Impfungen besonders wichtig sind, wo man sich beraten lassen kann und ob die Kosten von der Krankenkasse übernommen werden. ... more

Download (297)

View PDF (266)

Guideline for Adverse Drug Reactions Reporting for Healthcare Professionals

SAHPRA (2020) CC

Communication to Healthcare Professionals Mar-2020 This guideline is intended to assist healthcare professionals in the participation of very important process of continuous surveillance of safety and efficacy of the health products which are used in their clinical practice. Continuous evaluation o... more

Download (908)

View PDF (1618)

Guidance Note on Disability and Emergency Risk Management for Health

World Health Organization; UNICEF; UNISDR; et al. (2013) C_WHO

This guidance note is intended primarily for health actors working in emergency and disaster risk management (hereafter 'emergency risk management') at the local, national or international level, and in governmental or nongovernmental agencies. People with disabilities, those... more

Download (671)

View PDF (905)

Nepal: Monitoring the situation of children and women, Multiple Indicator Cluster Survey

Government of Nepal, National Planning Commission, Secretariat Central Bureau of Statistics, UNICEF (2014)

Download (155)

View PDF (148)

From Panic and Neglect to Investing in Health Security

The World Bank (2017) CC

Multiple pandemics, numerous outbreaks, thousands of lives lost and billions of dollars of national income wiped out—all since the turn of this century, in barely 17 years—and yet the world’s investments in pandemic preparedness and response remain woefully inadequate. We know by now that the ... more

Download (634)

View PDF (669)

Kenya: Multiple Indicator Cluster Survey 2013/14, Final Report

Kenya National Bureau of Statistics, UNICEF (2016)

Download (1910)

View PDF (2602)

HPV Vaccine Communication: Special considerations for a unique vaccine

World Health Organization WHO (2013) C_WHO

A lack of knowledge about the threat of vaccine-preventable diseases, risks and benefits of vaccines, mistrust of government and health workers, poor service delivery and alternative health or religious beliefs play a role in lower uptake of some vaccines. These challenges underscore the importance ... more

External Link

Behavioural and social drivers of vaccination: tools and practical guidance for achieving high uptake

World Health Organization WHO; UN Children´s Fund (2022) C_WHO

Tools and practical guidance for achieving high uptake

Download (159)

View PDF (490)

Guideline on management of pneumonia and diarrhoea in children up to 10 years of age

World Health Organization WHO (2024) C_WHO

Pneumonia and diarrhoea account for 23% of under-five mortality and were responsible for an estimated 1.17 million deaths in children under five globally. Furthermore, pneumonia and diarrhoea were responsible for 18% of mortality in children 5–9 years of age, resulting in an estimated 86 000 preve... more

Download (433)

View PDF (576)

Zambia: National Malaria Elimination Strategic Plan 2017-2021

National Malaria Elimination Centre, Ministry of Health, Zambia (2017) C2

Moving from accelerated burden reduction to malaria elimination in Zambia

Download (867)

View PDF (945)

WHO Country Cooperation Strategy 2008-2013 Malawi

World Health Organization (2009) C_WHO

Download (79)

View PDF (106)

Polio transition strategic framework: monitoring and evaluation

World Health Organization WHO (2024) C_WHO

The Polio Transition1 Monitoring and Evaluation (M&E) Framework was designed to monitor progress towards achieving the strategic and operational outcomes of the post-2023 Strategic Action Plan on Polio Transition (2018– 2023), as outlined in the Global Vision to use polio investments to build st... more

Download (687)

View PDF (1028)

Independent Monitoring Board of the Global Polio Eradication Initiative (Fifteenth Report: December 2017)

Global Polio Eradication Initiative (2017) C1

The report reviews progress with the task of planning and implementing measures necessary to secure a completely polio-free world. It also examines actions aimed at ensuring successful transfer of polio assets, innovations developed and lessons learned to countries’ public health programmes and ot... more

Download (5685)

View PDF (1595)

Pharmaceutical management and prescribing pattern of antimalarial drugs in the public health facilities in Dar-es-Salaam, Tanzania

Richard Sebastian Silumbe (2011) C1

Master of Science in Pharmaceutical Management Dissertation

Download (1390)

View PDF (2637)

Humanitarian Supply Management And Logistics In The Health Sector
recommended

Pan American Health Organization (2001)

Download (184)

View PDF (188)

Tuberculosis in the WHO African Region: 2023 progress update - September 2023

World Health Organisation (WHO) (2023) C_WHO

This brief update on tuberculosis (TB) in the African region covers the state of TB in the WHO African region, strategic priorities and targets and the impact of COVID-19 on essential services. This is followed by key figures for the region, the role of WHO in country support and, recognizing the im... more

Humanitarian Supply Management And Logistics In The Health Sector recommended

Humanitarian Supply Management And Logistics In The Health Sector
recommended